Program
pralsetinib
Also written as “Pralsetinib” and “pralsetinib (BLU-667)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Medullary, led by 2 companies.
Drug pagePralsetinib: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 62 open or running | phase 3since Jan 3, 2020 | Jan 20, 2017 | Nov 30, 2026phase 2 · NCT04302025 |
| Rigel Pharmaceuticals | 11 open or running | phase 4since Jul 9, 2026 | Jul 9, 2026 | Jul 30, 2027phase 4 · NCT07704658 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Rigel Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2018Named pralsetinibINNProposed as its International Nonproprietary Name in WHO's List 120
- Jul 9, 2026First study: phase 4 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07704658 · 12 planned · Spain
Ahead
- Jul 30, 2027Primary completion: phase 4 study in Carcinoma, Non-Small-Cell LungNCT07704658
TargetBeta
“An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, ”NCIt, by rule
“Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| selpercatinibrule | Eli Lilly | phase 4 | 19 |
Studies
The one study Rigel Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07704658Carcinoma, Non-Small-Cell Lung · Spain | 4 | Recruiting | Jul 30, 2027 | 12 |
How it is read
Names in the registry
- “Pralsetinib”, 6 entries
- “pralsetinib (BLU-667)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Carcinoma, Medullary, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.